AB Science today reports the analysis for its phase 3 trial evaluating masitinib in patients with non-resectable or metastatic stage 3 or stage 4 melanoma

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability